Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | VCAM1 | P19320 | 8/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18894117 | 0.87 | VCAM1 (0.62) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL9978247 | 0.83 | VCAM1 (0.58) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL994159 | 0.81 | ALDH1A1 (0.69) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL29550525 | 0.81 | VCAM1 (0.73) | ALDH1A1VCAM1HTTMEN1PKM | |
| SCHEMBL550564 | 0.81 | VCAM1 (0.73) | ALDH1A1VCAM1HTTMEN1PKM | |
| SCHEMBL133996 | 0.80 | VCAM1 (1.00) | ALDH1A1VCAM1HTTMEN1KMT2A | |
| SCHEMBL6417727 | 0.80 | VCAM1 (1.00) | ALDH1A1VCAM1HTTMEN1KMT2A | |
| SCHEMBL29510874 | 0.80 | VCAM1 (1.00) | ALDH1A1VCAM1HTTMEN1KMT2A | |
| SCHEMBL11651298 | 0.80 | ALDH1A1 (0.67) | ALDH1A1VCAM1HTTPOLBMEN1 | |
| SCHEMBL6215796 | 0.80 | VCAM1 (1.00) | ALDH1A1VCAM1HTTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | ALDH1A1 2743/4885VCAM1 1233/4885HTT 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.